These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 738348)

  • 1. Elimination of hexamethylene diisocyanate cross-linked polypeptides in patients with normal or impaired renal function.
    Köhler H; Kirch W; Fuchs P; Stalder K; Distler A
    Eur J Clin Pharmacol; 1978 Dec; 14(6):405-12. PubMed ID: 738348
    [No Abstract]   [Full Text] [Related]  

  • 2. Chromatographic study of hexamethylene diisocyanate cross-linked polypeptides in normal Nigerians.
    Sodipo JO; Akinrimisi EO
    Afr J Med Med Sci; 1980; 9(3-4):85-8. PubMed ID: 6283864
    [No Abstract]   [Full Text] [Related]  

  • 3. Single intravenous dose kinetics accumulation of atenolol in patients with impaired renal function and on hemodialysis.
    Kirch W; Schäfer M; Braun M
    Arch Toxicol Suppl; 1980; 4():366-9. PubMed ID: 6933939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ceftazidime in normal and impaired renal function.
    Höffler D; Koeppe P; Williams KJ
    Arzneimittelforschung; 1984; 34(1):72-6. PubMed ID: 6367755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elimination kinetics of mezlocillin in normal and impaired renal function including the effects of dialysis.
    Kosmidis J; Doundoulaki P; Stathakis C; Zerefos N; Bounia A; Daikos GK
    Arzneimittelforschung; 1979; 29(12a):1960-2. PubMed ID: 543901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of tritiated gentamicin in normal human subjects and in patients with severely impaired renal function.
    Wilson TW; Mahon WA; Inaba T; Johnson GE; Kadar D
    Clin Pharmacol Ther; 1973; 14(5):815-22. PubMed ID: 4729899
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of kidney function on the elimination and action of colloidal plasma substitutes].
    Köhler H
    Fortschr Med; 1979 Oct; 97(40):1809-13. PubMed ID: 94298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of norfloxacin (MK 366) in patients with impaired kidney function--some preliminary results.
    Hughes PJ; Webb DB; Asscher AW
    J Antimicrob Chemother; 1984 May; 13 Suppl B():55-7. PubMed ID: 6234276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefsulodin kinetics in renal impairment.
    Gibson TP; Granneman GR; Kallal JE; Sennello LT
    Clin Pharmacol Ther; 1982 May; 31(5):602-8. PubMed ID: 7075110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum elimination of HES in moderately reduced renal function].
    Schimetta W; Kröll W; Pölz W; Colombo T; Gassmayr SE; Sirtl C; List WF
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Aug; 37(8):468-74. PubMed ID: 12165916
    [No Abstract]   [Full Text] [Related]  

  • 11. Diseases of the urinary system. Prescribing for patients with renal failure.
    Sharpstone P
    Br Med J; 1977 Jul; 2(6078):36-7. PubMed ID: 871747
    [No Abstract]   [Full Text] [Related]  

  • 12. The influence of renal function on the elimination kinetics of sulbenicillin in man.
    Montanari A; Borghi L; Canali M; Coruzzi P; Novarini A; Borghetti A
    Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):225-8. PubMed ID: 7390672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of tenoxicam in patients with impaired renal function.
    Horber FF; Guentert TW; Weidekamm E; Heizmann P; Descoeudres C; Frey FJ
    Eur J Clin Pharmacol; 1986; 29(6):697-701. PubMed ID: 3709612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of indoprofen in patients with renal insufficiency (a preliminary report).
    Wibell L; Nilsson P; Lindström B
    Eur J Rheumatol Inflamm; 1981; 4(1):16-21. PubMed ID: 7341276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cinoxacin in normal volunteers and patients with impaired renal function.
    Ohkawa M; Sugata T; Sawaki M; Okasho A; Kuroda K; Yamada H
    J Antimicrob Chemother; 1981 Dec; 8(6):447-51. PubMed ID: 7333988
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of tocainide in patients with renal dysfunction and during haemodialysis.
    Wiegers U; Hanrath P; Kuck KH; Pottage A; Graffner C; Augustin J; Runge M
    Eur J Clin Pharmacol; 1983; 24(4):503-7. PubMed ID: 6407848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of ceftazidime in normal and impaired renal function.
    Höffler D; Koeppe P; Williams KJ
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():241-5. PubMed ID: 6352626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of cefadroxil in patients with impaired renal function.
    Leroy A; Humbert G; Godin M; Fillastre JP
    J Antimicrob Chemother; 1982 Sep; 10 Suppl B():39-46. PubMed ID: 7142092
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pharmacokinetics of azlocillin in impaired renal function and haemodialysis (author's transl)].
    Schurig R; Kampf D; Becker H; Förster D
    Arzneimittelforschung; 1979; 29(12a):1944-8. PubMed ID: 543896
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiple dose kinetics and drug dosage in patients with kidney disease.
    Dettli L; Spring P; Ryter S
    Acta Pharmacol Toxicol (Copenh); 1971; 29 Suppl 3():211-24. PubMed ID: 5316403
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.